Primary biliary cirrhosis

Orphanet Journal of Rare Diseases

Volumn 3, Issue 1, 2008, Pages

  Kumagi, Teru ^a   Heathcote, E Jenny ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CHOLAGOGUE; URSODEOXYCHOLIC ACID;

AGED; AUTOIMMUNE DISEASE; BILIARY CIRRHOSIS; FEMALE; HUMAN; IMMUNOLOGY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; REVIEW; SEX DIFFERENCE;

AGED; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; CHOLAGOGUES AND CHOLERETICS; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SEX FACTORS; URSODEOXYCHOLIC ACID;

EID: 40749083584     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-3-1     Document Type: Article

References (191)

1. Primary biliary cirrhosis. MM Kaplan ME Gerschwin, N Engl J Med 2005 353 1261 1273 10.1056/NEJMra043898 16177252
2. On a certain affection of the skin-vitiligoidea - plana -tuberosa. T Addison W Gull, Guys Hosp Rept 1851 7 G265 277
3. The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis. EH Ahrens Jr HG Kunkel, J Clin Invest 1949 28 1565 1574 15395959 10.1172/JCI102222
4. Primary biliary cirrhosis. Chronic non-suppurative destructive cholangitis. E Rubin F Schaffner H Popper, Am J Pathol 1965 46 387 407 14266218
5. Pediatric-onset primary biliary cirrhosis. Y Dahlan L Smith D Simmons LD Jewell I Wanless EJ Heathcote VG Bain, Gastroenterology 2003 125 1476 1479 10.1016/j.gastro.2003.08.022 14598264
6. A cross-sectional study of primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. F Sakaguchi M Mori M Zeniya G Toda, J Epidemiol 2005 15 24 28 10.2188/jea.15.24 15678923
7. Primary biliary cirrhosis. MM Kaplan, N Engl J Med 1987 26 521 528
8. The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales. AN Hamlyn S Sherlock, Gut 1974 15 473 479 4854819 10.1136/gut.15.6.473
9. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. A Danielsson L Boqvist P Uddenfeldt, Hepatology 1990 11 458 464 10.1002/hep.1840110317 2312058
10. The demography of primary biliary cirrhosis in Ontario, Canada. H Witt-Sullivan J Heathcote K Cauch L Blendis C Ghent A Katz R Milner SC Pappas J Rankin IR Wanless, Hepatology 1990 12 98 105 10.1002/hep.1840120116 2197212
11. Descriptive epidemiology of primary biliary cirrhosis in the province of Quebec. JP Villeneuve D Fenyves C Infante-Rivarde, Can J Gastroenterol 1991 5 174 178
12. Epidemiology and natural history of primary biliary cirrhosis in a US community. WR Kim KD Lindor GR Locke 3rd TM Therneau HA Homburger KP Batts BP Yawn JL Petz LJ Melton 3rd ER Dickson, Gastroenterology 2000 119 1631 1636 10.1053/gast.2000.20197 11113084
13. Prevalence of autoimmune liver disease in Alaska Natives. KJ Hurlburt BJ McMahon H Deubner B Hsu-Trawinski JL Williams KV Kowdley, Am J Gastroenterol 2002 97 2402 2407 10.1111/j.1572-0241.2002.06019.x 12358264
14. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. RG Watson PW Angus M Dewar B Goss RB Sewell RA Smallwood, Gut 1995 36 927 930 7615286 10.1136/gut.36.6.927
15. Primary biliary cirrhosis once rare, now common in the United Kingdom? OF James R Bhopal D Howel J Gray AD Burt JV Metcalf, Hepatology 1999 30 390 394 10.1002/hep.510300213 10421645
16. A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND Project Group, Diabetologia 1993 36 883 892 10.1007/BF02374468 8243865
17. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? M Myszor OF James, Q J Med 1990 75 377 385 2385742
18. The epidemiology of primary biliary cirrhosis. MI Prince OF James, Clin Liver Dis 2003 7 795 819 10.1016/S1089-3261(03)00102-8 14594132
19. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. J Van de Water A Cooper CD Surh R Coppel D Danner A Ansari R Dickson ME Gershwin, N Engl J Med 1989 320 1377 1380 2716784
20. Primary biliary cirrhosis. JA Talwalkar KD Lindor, Lancet 2003 362 53 61 10.1016/S0140-6736(03)13808-1 12853201
21. Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). T Nakano K Inoue J Hirohara S Arita K Higuchi M Omata G Toda, Hepatol Res 2002 22 250 260 10.1016/S1386-6346(01)00148-6 11929710
22. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. M Prince A Chetwynd W Newman JV Metcalf OF James, Gastroenterology 2002 123 1044 1051 10.1053/gast.2002.36027 12360466
23. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. F Colina F Pinedo JA Solis D Moreno M Nevado, Gastroenterology 1992 102 1319 1324 1551537
24. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. PM Huet J Deslauriers A Tran C Faucher J Charbonneau, Am J Gastroenterol 2000 95 760 767 10.1111/j.1572-0241.2000.01857.x 10710071
25. Fatigue in primary biliary cirrhosis. K Cauch-Dudek S Abbey DE Stewart EJ Heathcote, Gut 1998 43 705 710 9824355
26. The true impact of fatigue in primary biliary cirrhosis: a population study. J Goldblatt PJ Taylor T Lipman MI Prince A Baragiotta MF Bassendine OF James DE Jones, Gastroenterology 2002 122 1235 1241 10.1053/gast.2002.32993 11984509
27. Cholestatic liver diseases and health-related quality of life. ZM Younossi ML Kiwi N Boparai LL Price G Guyatt, Am J Gastroenterol 2000 95 497 502 10.1111/j.1572-0241.2000.01774.x 10685757
28. The natural history of abdominal pain associated with primary biliary cirrhosis. JM Laurin CK DeSotel RA Jorgensen ER Dickson KD Lindor, Am J Gastroenterol 1994 89 1840 1843 7942679
29. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. MI Prince A Chetwynd WL Craig JV Metcalf OF James, Gut 2004 53 865 870 15138215 10.1136/gut.2003.023937
30. Primary biliary cirrhosis showing a high titer of autoantibody; report of a case. IR Mackay, N Engl J Med 1958 258 185 188 13493762
31. IgM in primary biliary cirrhosis. Physicochemical and complement activating properties. S Lindgren S Eriksson, J Lab Clin Med 1982 99 636 645 7069268
32. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? S Joshi K Cauch-Dudek EJ Heathcote K Lindor R Jorgensen R Klein, Am J Gastroenterol 2002 97 999 1002 10.1111/j.1572-0241.2002. 05620.x 12003438
33. Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis. A Grantio P Muratori L Muratori G Pappas F Cassani J Worthington M Guindi S Ferri C De Molo M Lenzi RW Chapman FB Bianchi, Aliment Pharmacol Ther 2006 24 1575 1583 10.1111/j.1365-2036.2006.03172.x 17206945
34. Primary biliary cirrhosis: clinical, pathologic, and helical CT findings in 53 patients. A Blacher MP Federle G Brancatelli, Radiology 2001 220 329 336 11477233
35. Primary biliary cirrhosis. PJ Scheuer, Proc R Soc Med 1967 60 1257 1260 6066569
36. Nonsuppurative destructive chronic cholangitis and chronic hepatitis. H Popper F Schaffner, Progress in liver diseases New York: Grune & Stratton, Inc, Popper H, Schaffner F, 1970 3 336 354 4908705
37. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). J Ludwig ER Dickson GS McDonald, Virchows Arch. A Pathol Pathol Anat 1978 379 103 112 10.1007/BF00432479
38. Sampling variability of liver fibrosis in chronic hepatitis C. P Bedossa D Dargere V Paradis, Hepatology 2003 38 1449 1457 14647056
39. Autoimmune associations in primary biliary cirrhosis. KS Culp CR Fleming J Duffy WP Baldus ER Dickson, Mayo Clin Proc 1982 57 365 370 6896227
40. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. FE Watt OF James DE Jones, QJM 2004 97 397 406 10.1093/qjmed/hch078 15208427
41. Association of clonally expanded T cells with the syndrome of primary biliary cirrhosis and limited scleroderma. MJ Mayo RN Jenkins B Combes PE Lipsky, Hepatology 1999 29 1635 1642 10.1002/hep.510290637 10347101
42. Characterization of antimitochondrial antibodies in health adults. A Mattalia S Quaranta PS Leung M Bauducci J Van de Water PL Calvo F Danielle M Rizzetto A Ansari RL Coppel F Rosina ME Gershwin, Hepatology 1998 27 656 661 10.1002/hep.510270303 9500690
43. Impact of the operator's experience on value of high-resolution transabdominal ultrasound in the diagnosis of choledocholithiasis: a prospective comparison using endoscopic retrograde cholangiography as the gold standard. S Rickes G Treiber K Monkemuller U Peitz A Csepregi S Kahl A Vopel K Wolle MP Ebert S Klauck P Malfertheiner, Scand J Gastroenterol 2006 41 838 843 10.1080/00365520500515370 16785198
44. Sclerosing cholangitis: a focus on secondary causes. R Abdalian EJ Heathcote, Hepatology 2006 44 1063 1074 10.1002/hep.21405 17058222
45. Liver disease in cystic fibrosis a prospective study on incidence, risk factors, and outcome. C Colombo PM Battezzati A Crosigniani A Morabito D Costantini R Padoan A Giunta, Hepatology 2002 36 1374 1382 12447862
46. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. R Poupon O Chazouilleres C Corpechot Y Chretien, Hepatology 2006 44 85 90 10.1002/hep.21229 16799997
47. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. JG Kingham DR Parker, Gut 1998 42 120 122 9518232
48. Celiac disease and risk of liver disease: a general population-based study. JF Ludvigsson P Elfstrom U Broome A Ekbom SM Montgomery, Clin Gastroenterol Hepatol 2007 5 63 69 10.1016/j.cgh.2006.09.034 17161656
49. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. K Kaukinen L Halme P Collin M Farkkila M Maki P Vehmanen J Partanen K Hockerstedt, Gastroenterology 2002 122 881 888 10.1053/gast.2002.32416 11910339
50. Liver tests in hyperthyroidism: effect of antithyroid therapy. A Gürlek V Cobankara M Bayraktar, J Clin Gastroenterol 1997 24 180 183 10.1097/00004836-199704000-00013 9179740
51. Familial primary biliary cirrhosis reassessed: a geographically-based population study. DE Jones FE Watt JV Metcalf MF Bassendine OF James, J Hepatol 1999 30 402 407 10.1016/S0168-8278(99)80097-X 10190721
52. Prevalence and pattern of familial disease in primary biliary cirrhosis. AM Brind GP Bray BC Portmann R Williams, Gut 1995 36 615 617 7737573 10.1136/gut.36.4.615
53. Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis. PL Bittencourt AQ Farias CP Abrantes-Lemos LL Goncalves PL Goncalves EP Magalhaes FJ Carrilho AA Laudanna EL Cancado, J Gastroenterol Hepatol 2004 19 873 878 10.1111/j.1440-1746.2004. 03396.x 15242489
54. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. C Selmi MJ Mayo N Bach H Ishibashi P Invernizzi RG Gish SC Gordon HI Wright B Zweiban M Podda ME Gershwin, Gastroenterology 2004 127 485 492 10.1053/j.gastro.2004.05.005 15300581
55. Frequency of monosomy X in women with primary biliary cirrhosis. P Invernizzi M Miozzo PM Battezzati I Bianchi FR Grati G Simoni C Selmi M Watnik ME Gershwin M Podda, Lancet 2004 363 533 535 10.1016/S0140-6736(04)15541-4 14975617
56. Primary biliary cirrhosis in a patient with Turner syndrome. P Milkiewicz J Heathcote, Can J Gastroenterol 2005 19 631 633 16247527
57. Bacteriuria and primary biliary cirrhosis. AK Burroughs IJ Rosenstein O Epstein JM Hamilton-Miller W Brumfitt S Sherlock, Gut 1984 25 133 137 6363217 10.1136/gut.25.2.133
58. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. U Hopf B Moller R Stemerowicz H Lobeck A Rodloff M Freudenberg C Galanos D Huhn, Lancet 1989 2 1419 1422 10.1016/S0140-6736(89)92034-5 2574361
59. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. C Selmi DL Balkwill P Invernizzi AA Ansari RL Coppel M Podda PS Leung TP Kenny J Van De Water MH Nantz MJ Kurth ME Gershwin, Hepatology 2003 38 1250 1257 10.1053/jhep.2003.50446 14578864
60. Is there a relation between Chlamydia infection and primary biliary cirrhosis? PS Leung O Park S Matsumura AA Ansari RL Coppel ME Gershwin, Clin Dev Immunol 2003 10 227 233 10.1080/10446670310001642429 14768955
61. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? AS Abdulkarim LM Petrovic WR Kim P Angulo RV Lloyd KD Lindor, J Hepatol 2004 40 380 384 10.1016/j.jhep.2003.11.033 15123349
62. Atrophic corpus gastritis and Helicobacter pylori infection in primary biliary cirrhosis. K Dohmen H Shigematsu Y Miyamoto F Yamasaki K Irie H Ishibashi, Dig Dis Sci 2002 47 162 169 10.1023/A:1013292210036 11837719
63. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. L Vilagut J Vila O Vinas A Pares A Gines MT Jimenez de Anta J Rodes, J Hepatol 1994 21 673 677 10.1016/S0168-8278(94)80117-7 7529275
64. Primary biliary cirrhosis: New thoughts on pathophysiology and treatment. A Mason S Nair, Curr Gastroenterol Rep 2002 4 45 51 10.1007/s11894-002-0037-8 11825541
65. Does a betaretrovirus infection trigger primary biliary cirrhosis? L Xu Z Shen L Guo B Fodera A Keogh R Joplin B O'Donnell J Aitken W Carman J Neuberger A Mason, Proc Natl Acad Sci 2003 100 8454 8459 12832623 10.1073/pnas.1433063100
66. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. AL Mason GH Farr L Xu SG Hubscher JM Neuberger, Am J Gastroenterol 2004 99 2348 2355 10.1111/j.1572-0241.2004.40741.x 15571581
67. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. C Selmi SR Ross AA Ansari P Invernizzi M Podda RL Coppel ME Gershwin, Gastroenterology 2004 127 493 501 10.1053/j.gastro.2004.05.033 15300582
68. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. A Parikh-Patel EB Gold H Worman KE Krivy ME Gershwin, Hepatology 2001 33 16 21 10.1053/jhep.2001.21165 11124815
69. An exploratory population-based case-control study of primary biliary cirrhosis. D Howel CM Fischbacher RS Bhopal J Gray JV Metcalf OF James, Hepatology 2000 31 1055 1060 10.1053/he.2000.7050 10796879
70. Lack of association between appendectomy and primary biliary cirrhosis. EI Rigopoulou SP Georgiadou S Barbanis GN Dalekos, Scand J Gastroenterol 2006 41 573 576 10.1080/00365520500319633 16638700
71. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. DP Bogdanos H Baum UC Sharma A Grasso Y Ma AK Burroughs D Vergani, J Hepatol 2002 36 14 21 10.1016/S0168-8278(01)00252-5 11804659
72. The role of Yersinia enterocolitica in appendicitis in the southwestern United States. RS Bennion JE Thompson Jr J Gil PJ Schmit, Am Surg 1991 57 766 768 1746791
73. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. SA Long C Quan J Van de Water MH Nantz MJ Kurth D Barsky ME Colvin KS Lam RL Coppel A Ansari ME Gershwin, J Immunol 2001 167 2956 2963 11509645
74. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. K Amano PS Leung R Rieger C Quan X Wang J Marik YF Suen MJ Kurth MH Nantz AA Ansari KS Lam M Zeniya E Matsuura RL Coppel ME Gershwin, J Immunol 2005 174 5874 5883 15845458
75. USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. ME Gershwin C Selmi HJ Worman EB Gold M Watnik J Utts KD Lindor MM Kaplan JM Vierling, Hepatology 2005 42 1194 1202 10.1002/hep.20907 16250040
76. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. CO Zein K Beatty AB Post L Logan S Debanne AJ McCullough, Hepatology 2006 44 1564 1571 10.1002/hep.21423 17133468
77. Primary biliary cirrhosis: an epidemiological study. DR Triger, Br Med J 1980 281 772 775 7427444
78. Primary biliary cirrhosis among atomic bomb survivors in Nagasaki, Japan. K Ohba K Omagari H Kinoshita H Soda J Masuda H Hazama M Tagawa T Hata H Nakamura I Murata S Kohno, J Clin Epidemiol 2001 54 845 850 10.1016/S0895- 4356(00)00370-X 11470395
79. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. A Ala CM Stanca M Bu-Ghanim I Ahmado AD Branch TD Schiano JA Odin N Bach, Hepatology 2006 43 525 531 10.1002/hep.21076 16496326
80. Acute Liver Failure Study Group. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. PS Leung L Rossaro PA Davis O Park A Tanaka K Kikuchi H Miyakawa GL Norman W Lee ME Gershwin, Hepatology 2007 46 1436 1442 10.1002/hep.21828 17657817
81. Site-directed mutagenesis of lysine within the immunodominant autoepitope of PDC-E2. PS Leung T Iwayama RL Coppel ME Gershwin, Hepatology 1990 12 1321 1328 10.1002/hep.1840120612 1701753
82. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. M Nakamura Y Shimizu-Yoshida Y Takii A Komori T Yokoyama T Ueki M Daikoku K Yano T Matsumoto K Migita H Yatsuhashi M Ito N Masaki H Adachi Y Watanabe Y Nakamura T Saoshiro T Sodeyama M Koga S Shimoda H Ishibashi, J Hepatol 2005 42 386 392 10.1016/j.jhep.2004.11.016 15710222
83. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. M Nakamura Y Takii M Ito A Komori T Yokoyama Y Shimizu-Yoshida M Koyabu M Matsuyama T Mori T Kamihira M Daikoku K Migita H Yatsuhashi N Nozaki S Shimoda H Ishibashi, J Autoimmun 2006 26 138 145 10.1016/j.jaut.2005.10.007 16337775
84. Distribution of pyruvate dehydrogenase dihydrolipoamide acetyltransferase (PDC-E2) and another mitochondrial marker in salivary gland and biliary epithelium from patients with primary biliary cirrhosis. RE Joplin GD Johnson JB Matthews J Hamburger JG Lindsay SG Hubscher AJ Strain JM Neuberger, Hepatology 1994 19 1375 1380 8188168
85. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. JA Odin RC Huebert L Casciola-Rosen NF LaRusso A Rosen, J Clin Invest 2001 108 223 232 11457875 10.1172/JCI200110716
86. Expression of Bcl-2 familial proteins is reduced in small bile duct lesions of primary biliary cirrhosis. M Iwata K Harada N Kono S Kaneko K Kobayashi Y Nakanuma, Hum Pathol 2000 31 179 184 10.1016/S0046-8177(00)80217-8 10685631
87. T cell responses to the putative dominant autoepitope in primary biliary cirrhosis (PBC). JM Palmer AG Diamond SJ Yeaman MF Bassendine DE Jones, Clin Exp Immunol 1999 116 133 139 10209517 10.1046/j.1365-2249.1999.00803.x
88. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. H Kita S Matsumura XS He AA Ansari ZX Lian J Van de Water RL Coppel MM Kaplan ME Gershwin, J Clin Invest 2002 109 1231 1240 11994412 10.1172/JCI200214698
89. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. H Kita ZX Lian J Van de Water XS He S Matsumura M Kaplan V Luketic RL Coppel AA Ansari ME Gershwin, J Exp Med 2002 195 113 123 10.1084/jem.20010956 11781370
90. Analysis of TCR antagonism and molecular mimicry of an HLA-A0201-restricted CTL epitope in primary biliary cirrhosis. H Kita S Matsumura XS He AA Ansari ZX Lian J Van de Water RL Coppel MM Kaplan ME Gershwin, Hepatology 2002 36 918 926 12297839
91. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Irie Y Wu LS Wicker D Rainbow MA Nalesnik R Hirsch LB Peterson PS Leung C Cheng IR Mackay ME Gershwin WM Ridgway, J Exp Med 2006 203 1209 1219 16636131 10.1084/jem.20051911
92. IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. K Wakabayashi ZX Lian Y Moritoki RY Lan K Tsuneyama YH Chuang GX Yang W Ridgway Y Ueno AA Ansari RL Coppel IR Mackay ME Gershwin, Hepatology 2006 44 1240 1249 10.1002/hep.21385 17058261
93. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. S Oertelt ZX Lian CM Cheng YH Chuang KA Padgett XS He WM Ridgway AA Ansari RL Coppel MO Li RA Flavell M Kronenberg IR Mackay ME Gershwin, J Immunol 2006 177 1655 1660 16849474
94. The cholangiopathies: disorders of biliary epithelia. KN Lazaridis M Strazzabosco NF Larusso, Gastroenterology 2004 127 1565 1577 10.1053/j.gastro.2004.08.006 15521023
95. A bipotential precursor population for pancreas and liver within the embryonic endoderm. G Deutsch J Jung M Zheng J Lora KS Zaret, Development 2001 128 871 881 11222142
96. Hedgehog signaling maintains resident hepatic progenitors throughout life. JK Sicklick YX Li A Melhem E Schmelzer M Zdanowicz J Huang M Caballero JH Fair JW Ludlow RE McClelland LM Reid AM Diehl, Am J Physiol Gastrointest Liver Physiol 2006 290 G859 870 10.1152/ajpgi.00456.2005 16322088
97. Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis. Y Jung SJ McCall YX Li AM Diehl, Hepatology 2007 45 1091 1096 10.1002/hep.21660 17464985
98. Trials in primary biliary cirrhosis: need for the right drugs at the right time. R Poupon, Hepatology 2004 39 900 902 10.1002/hep.20188 15057890
99. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. U Leuschner H Fischer W Kurtz S Güldütuna K Hübner A Hellstern M Gatzen M Leuschner, Gastroenterology 1989 97 1268 1274 2551765
100. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. EJ Heathcote K Cauch-Dudek V Walker RJ Bailey LM Blendis CN Ghent P Michieletti GY Minuk SC Pappas LJ Scully, Hepatology 1994 19 1149 1156 8175136
101. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. A Pares L Caballeria J Rodes M Bruguera L Rodrigo A Garcia-Plaza J Berenguer D Rodriguez-Martinez J Mercader R Velicia, J Hepatol 2000 32 561 566 10.1016/S0168-8278(00)80216-0 10782903
102. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. RE Poupon KD Lindor K Cauch-Dudek ER Dickson R Poupon EJ Heathcote, Gastroenterology 1997 113 884 890 10.1016/S0016-5085(97) 70183-5 9287980
103. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. JL Siegel R Jorgensen P Angulo KD Lindor, J Clin Gastroenterol 2003 37 183 185 10.1097/00004836-200308000-00018 12869893
104. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. RE Poupon AM Bonnand Y Chretien R Poupon, Hepatology 1999 29 1668 1671 10.1002/hep.510290603 10347106
105. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. C Corpechot F Carrat AM Bonnand RE Poupon R Poupon, Hepatology 2000 32 1196 1199 10.1053/jhep.2000.20240 11093724
106. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. KD Lindor RA Jorgensen TM Therneau M Malinchoc ER Dickson, Mayo Clin Proc 1997 72 1137 1140 9413293
107. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. A Pares L Caballeria J Rodes, Gastroenterology 2006 130 715 720 10.1053/j.gastro.2005.12.029 16530513
108. Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. M Koulentaki J Moscandrea P Dimoulios C Chatzicostas EA Kouroumalis, Dig Dis Sci 2004 49 1190 5 10.1023/B:DDAS.0000037811.48575.da 15387345
109. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. PC ter Borg SW Schalm BE Hansen HR van Buuren Dutch PBC Study Group, Am J Gastroenterol 2006 101 2044 50 10.1111/j.1572-0241.2006.00699.x 16848809
110. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. J Shi C Wu Y Lin YX Chen L Zhu WF Xie, Am J Gastroenterol 2006 101 1529 1538 10.1111/j.1572-0241. 2006.00634.x 16863557
111. Ursodeoxycholic Acid for Patients With Primary Biliary Cirrhosis: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials Using Bayesian Approach as Sensitivity Analyses. Y Gong Z Huang E Christensen C Gluud, Am J Gastroenterol 2007 102 1799 1807 10.1111/j.1572-0241.2007.01235.x 17459023
112. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. J Palma H Reyes J Ribalta J Iglesias MC Gonzalez I Hernandez C Alvarez C Molina AM Danitz, Hepatology 1992 15 1043 7 10.1002/hep.1840150612 1592342
113. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. M Leuschner KP Maier J Schlichting S Strahl G Herrmann HH Dahm H Ackermann J Happ U Leuschner, Gastroenterology 1999 117 918 925 10.1016/S0016-5085(99)70351-3 10500075
114. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. H Rautiainen P Karkkainen AL Karvonen H Nurmi P Pikkarainen H Nuutinen M Farkkila, Hepatology 2005 41 747 752 10.1002/hep.20646 15754377
115. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. H Rautiainen M Farkkila M Neuvonen T Sane AL Karvonen H Nurmi P Karkkainen PJ Neuvonen JT Backman, Aliment Pharmacol Ther 2006 24 1545 1552 10.1111/j.1365-2036.2006.03155.x 17206943
116. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. P Angulo RA Jorgensen JC Keach ER Dickson C Smith KD Lindor, Hepatology 2000 31 318 323 10.1002/hep.510310209 10655252
117. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. HC Mitchison JM Palmer MF Bassendine AJ Watson CO Record OF James, J Hepatol 1992 15 336 344 10.1016/0168-8278(92)90065-W 1447500
118. A prospective controlled trial of azathioprine in primary biliary cirrhosis. J Heathcote A Ross S Sherlock, Gastroenterology 1976 70 656 660 770224
119. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. RH Wiesner J Ludwig KD Lindor RA Jorgensen WP Baldus HA Homburger ER Dickson, N Engl J Med 1990 322 1419 1424 2184355
120. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. JA Talwalkar P Angulo JC Keach JL Petz RA Jorgensen KD Lindor, J Clin Gastroenterol 2005 39 168 171 10.1097/01.mcg.0000177230.13770.4e 15681915
121. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. KD Lindor ER Dickson RA Jorgensen ML Anderson RH Wiesner GJ Gores SM Lange SS Rossi AF Hofmann WP Baldus, Hepatology 1995 22 1158 1162 7557866
122. Randomized trial of chlorambucil for primary biliary cirrhosis. JH Hoofnagle GL Davis DF Schafer M Peters MI Avigan SC Pappas RG Hanson GY Minuk GM Dusheiko G Campbell, Gastroenterology 1986 91 1327 1334 3533699
123. Trial of penicillamine in advanced primary biliary cirrhosis. ER Dickson TR Fleming RH Wiesner WP Baldus CR Fleming J Ludwig JT McCall, N Engl J Med 1985 312 1011 1015 3885033
124. A prospective trial of colchicine for primary biliary cirrhosis. MM Kaplan DW Alling HJ Zimmerman HJ Wolfe RA Sepersky GS Hirsch GH Elta KA Glick KA Eagen, N Engl J Med 1986 315 1448 1454 3537784
125. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. P Angulo T Patel RA Jorgensen TM Therneau KD Lindor, Hepatology 2000 32 897 900 10.1053/jhep.2000. 18663 11050036
126. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. T Kurihara A Niimi A Maeda M Shigemoto K Yamashita, Am J Gastroenterol 2000 95 2990 2992 10.1111/j.1572-0241.2000.03220.x 11051391
127. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? MR Kilmurry EJ Heathcote K Cauch-Dudek K O'Rourke RJ Bailey LM Blendis CN Ghent GY Minuk SC Pappas LJ Scully UP Steinbrecher LR Sutherland CN Williams LJ Worobetz, Hepatology 1996 23 1148 1153 8621147
128. Optimal timing of liver transplantation for patients with primary biliary cirrhosis: use of prognostic modelling. E Christensen B Gunson J Neuberger, J Hepatol 1999 30 285 292 10.1016/S0168-8278(99)80075-0 10068109
129. Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history. PB Sylvestre KP Batts LJ Burgart JJ Poterucha RH Wiesner, Liver Transpl 2003 9 1086 1093 10.1053/jlts.2003.50213 14526404
130. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. J Levitsky J Hart SM Cohen HS Te, Liver Transpl 2003 9 733 736 10.1053/jlts.2003.50132 12827561
131. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. J Neuberger B Gunson S Hubscher P Nightingale, Liver Transpl 2004 10 488 491 10.1002/lt.20123 15048790
132. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. EQ Sanchez MF Levy RM Goldstein CG Fasola GW Tillery GJ Netto DL Watkins JS Weinstein NG Murray D Byers LL Christensen GB Klintmalm, Transplantation 2003 76 1583 1588 10.1097/01.TP.0000090867.83666.F7 14702528
133. Liver transplantation for nonviral, nonmalignant diseases: Problem of recurrence. JF Renz NL Ascher, World J Gastroenterol 2002 26 247 256
134. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. O Chazouilleres D Wendum L Serfaty S Montembault O Rosmorduc R Poupon, Hepatology 1998 28 296 301 10.1002/hep.510280203 9695990
135. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. JA Talwalkar JC Keach P Angulo KD Lindor, Am J Gastroenterol 2002 97 1191 1197 10.1111/j.1572-0241.2002.05703.x 12014727
136. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. S Joshi K Cauch-Dudek IR Wanless KD Lindor R Jorgensen K Batts EJ Heathcote, Hepatology 2002 35 409 413 10.1053/jhep.2002.30902 11826416
137. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. O Chazouilleres D Wendum L Serfaty O Rosmorduc R Poupon, J Hepatol 2006 44 J400 406 10.1016/j.jhep.2005.10. 017
138. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. P Michieletti IR Wanless A Katz PJ Scheuer SJ Yeaman MF Bassendine JM Palmer EJ Heathcote, Gut 1994 35 260 265 8307480 10.1136/gut.35.2.260
139. Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Stone JA Wade K Cauch-Dudek C Ng KD Lindor EJ Heathcote, J Hepatol 2002 36 8 13 10.1016/S0168-8278(01)00237-9 11804658
140. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. P Tandon BH Rowe B Vandermeer VG Bain, Am J Gastroenterol 2007 102 1528 1536 10.1111/j.1572-0241.2007.01200.x 17403073
141. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. S Khurana P Singh, Liver Int 2006 26 943 948 10.1111/j.1478-3231.2006.01326.x 16953834
142. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. VL Ng FC Ryckman G Porta IK Miura E de Carvalho MF Servidoni JA Bezerra WF Balistreri, J Pediatr Gastroenterol 2000 30 152 156 10.1097/00005176-200002000-00011
143. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. JM Stapelbroek KJ van Erpecum LW Klomp NG Venneman TP Schwartz GP van Berge Henegouwen J Devlin CM van Nieuwkerk AS Knisely RH Houwen, Hepatology 2006 43 51 53 10.1002/hep.20998 16374853
144. Role of plasmapheresis in primary biliary cirrhosis. LB Cohen EP Ambinder AM Wolke SP Field F Schaffiner, Gut 1985 26 291 294 3972276 10.1136/gut.26.3.291
145. Opioid peptides and primary biliary cirrhosis. JR Thornton MS Losowsky, BMJ 1988 297 1501 1504 3147046
146. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. NV Bergasa TL Talbot DW Alling JM Schmitt EC Walker BL Baker JC Korenman Y Park JH Hoofnagle EA Jones, Gastroenterology 1992 102 544 549 1732125
147. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. CA McRae MI Prince M Hudson CP Day OF James DE Jones, Gastroenterology 2003 125 591 596 10.1016/S0016-5085(03)00879-5 12891561
148. Sertraline as a first-line treatment for cholestatic pruritus. MJ Mayo I Handem S Saldana H Jacobe Y Getachew AJ Rush, Hepatology 2007 45 666 674 10.1002/hep.21553 17326161
149. Ursodeoxycholic acid for primary biliary cirrhosis. C Gluud E Christensen, Cochrane Database Syst Rev 2002 1 CD000551 11869580
150. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. PA McCormick F Scott O Epstein AK Burroughs PJ Scheuer N McIntyre, J Hepatol 1994 21 496 499 10.1016/S0168-8278(94)80092-8 7814794
151. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. MI Prince HC Mitchison D Ashley DA Burke N Edwards MG Bramble OF James DE Jones, Aliment Pharmacol Ther 2003 17 137 143 10.1046/j.1365-2036. 2003.01398.x 12492743
152. Primary biliary cirrhosis: report of a focus study group. NV Bergasa A Mason A Floreani J Heathcote MG Swain DE Jones KM Lindor MF Bassendine HJ Worman, Hepatology 2004 40 1013 1020 15382160
153. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. JJ Theal MN Toosi L Girlan RJ Heslegrave PM Huet KW Burak M Swain GA Tomlinson EJ Heathcote, Hepatology 2005 41 1305 1312 10.1002/hep.20698 15915460
154. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. MA Babatin FM Sanai MG Swain, Aliment Pharmacol Ther 2006 24 813 820 10.1111/j.1365-2036.2006.03048.x 16918885
155. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. JL Newton GJ Gibson M Tomlinson K Wilton D Jones, Hepatology 2006 44 91 98 10.1002/hep.21230 16800007
156. Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis. JL Newton M Hudson P Tachtatzis K Sutcliffe J Pairman JA Burt DE Jones, Hepatology 2007 45 1496 1505 10.1002/hep.21609 17538969
157. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. DE Jones JL Newton, Aliment Pharmacol Ther 2007 25 471 476 17270003
158. Bone loss and reduced osteoblast function in primary biliary cirrhosis. SF Hodgson ER Dickson HW Wahner KA Johnson KG Mann BL Riggs, Ann Intern Med 1985 103 855 860 4062087
159. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. SF Hodgson ER Dickson R Eastell EF Eriksen SC Bryant BL Riggs, Bone 1993 14 819 827 10.1016/8756-3282(93)90310-7 8155404
160. Serum vitamin D metabolites are not responsible for low turnover osteoporosis in chronic liver disease. T Diamond D Stiel R Mason D Lissner D Bikle S Wilson S Posen, J Clin Endocrinol Metab 1989 69 1234 1238 2584358
161. Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. R Olsson C Johansson G Lindstedt D Mellstrom, Scand J Gastroenterol 1994 29 753 756 10.3109/00365529409092505 7973437
162. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. JE Springer DE Cole LA Rubin K Cauch-Dudek L Harewood J Evrovski VD Peltekova EJ Heathcote, Gastroenterology 2000 118 145 151 10.1016/S0016-5085(00)70423-9 10611163
163. Osteoporosis in primary biliary cirrhosis revisited. J Newton R Francis M Prince O James M Bassendine D Rawlings D Jones, Gut 2001 49 282 287 11454807 10.1136/gut.49.2.282
164. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. KV Menon P Angulo S Weston ER Dickson KD Lindor, J Hepatol 2001 35 316 323 10.1016/S0168-8278(01)00144-1 11592591
165. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. N Guanabens A Pares I Ros L Caballeria F Pons S Vidal A Monegal P Peris J Rodes, J Hepatol 2005 42 573 577 10.1016/j.jhep.2004.11.035 15763344
166. Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. L Le Gars C Grandpierre O Chazouilleres F Berenbaum R Poupon, Joint Bone Spine 2002 69 195 200 10.1016/S1297-319X(02)00364-0 12027312
167. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. M Solaymani-Dodaran TR Card GP Aithal J West, Gastroenterology 2006 131 1752 1757 10.1053/j.gastro.2006.09.012 17087953
168. Bone mineral density before and after OLT: long-term follow-up and predictive factors. MM Guichelaar R Kendall M Malinchoc JE Hay, Liver Transpl 2006 12 1390 1402 10.1002/lt.20874 16933236
169. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. RH Boone AM Cheung LM Girlan EJ Heathcote, Dig Dis Sci 2006 51 1103 1112 10.1007/s10620-006-8015-x 16865577
170. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. N Guanabens A Pares I Ros L Alvarez F Pons L Caballeria A Monegal MJ Martinez de Osaba M Roca P Peris J Rodes, Am J Gastroenterol 2003 98 2268 2274 14572578
171. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. S Nishiguchi S Shimoi H Kurooka A Tamori D Habu T Takeda S Kubo, J Hepatol 2001 35 543 545 10.1016/S0168-8278(01)00133-7 11682046
172. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? B Bressler R Pinto D El-Ashry EJ Heathcote, Gut 2005 54 407 410 10.1136/gut.2004.040832 15710991
173. Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. TF Imperiale RW Klein N Chalasani, Hepatology 2007 45 870 878 10.1002/hep.21605 17393528
174. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. RJ Groszmann G Garcia-Tsao J Bosch ND Grace AK Burroughs R Planas A Escorsell JC Garcia-Pagan D Patch DS Matloff H Gao R Makuch Portal Hypertension Collaborative Group, N Engl J Med 2005 353 2254 2261 10.1056/NEJMoa044456 16306522
175. Earlier recurrence of esophageal varices, following therapy, in patients with primary biliary cirrhosis (PBC) compared with non-PBC patients. E Takeshita H Matsui N Shibata S Furukawa T Yokota H Murakami Y Ikeda Y Hiasa B Matsuura K Michitaka M Onji, J Gastroenterol 2004 39 1085 1089 10.1007/s00535-004-1447-1 15580402
176. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. PK Nijhawan TM Therneau ER Dickson J Boynton KD Lindor, Hepatology 1999 29 1396 1398 10.1002/hep.510290511 10216121
177. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. L Caballería A Parés A Castells A Ginés C Bru J Rodés, Am J Gastroenterol 2001 96 1160 1163 11316164
178. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. A Suzuki J Lymp J Donlinger F Mendes P Angulo K Lindor, Clin Gastroenterol Hepatol 2007 5 259 264 10.1016/j.cgh.2006.09.031 17174610
179. Clinical features of symptomatic primary biliary cirrhosis initially complicated with esophageal varices. Y Murata M Abe S Furukawa T Kumagi H Matsui K Matsuura Y Hiasa M Onji, J Gastroenterol 2006 41 1220 1226 10.1007/s00535-006-1914-y 17287902
180. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. A Shibuya K Tanaka H Miyakawa M Shibata M Takatori K Sekiyama N Hashimoto S Amaki T Komatsu T Morizane, Hepatology 2002 35 1172 1178 10.1053/jhep.2002.33157 11981767
181. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. J Springer K Cauch-Dudek K O'Rourke IR Wanless EJ Heathcote, Am J Gastroenterol 1999 94 47 53 10.1111/j.1572-0241.1999.00770.x 9934730
182. Primary biliary cirrhosis: clinical features and outcome with special reference to asymptomatic disease. A Nyberg L Loof, Scand J Gastroenterol 1989 24 57 64 10.3109/00365528909092240 2928724
183. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. TC Mahl W Shockcor JL Boyer, J Hepatol 1994 20 707 713 10.1016/S0168-8278(05)80139-4 7930469
184. Diminished survival in primary biliary cirrhosis. K Balasubramaniam PM Grambsch RH Wiesner KD Lindor ER Dickson, Gastroenterology 1990 98 1567 1571 2338193
185. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. J Roll JL Boyer D Barry G Klatskin, N Engl J Med 1983 308 1 7 6847917
186. Time course of histological progression in primary biliary cirrhosis. GR Locke 3rd TM Therneau J Ludwig ER Dickson KD Lindor, Hepatology 1996 23 52 56 10.1002/hep.510230108 8550048
187. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. C Corpechot F Carrat R Poupon RE Poupon, Gastroenterology 2002 122 652 658 10.1053/gast.2002.31880 11874998
188. Asymptomatic primary biliary cirrhosis: a progress report on long-term follow-up and natural history. DR Beswick G Klatskin JL Boyer, Gastroenterology 1985 89 267 271 4007417
189. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. M Nakamura H Kondo T Mori A Komori M Matsuyama M Ito Y Takii M Koyabu T Yokoyama K Migita M Daikoku S Abiru H Yatsuhashi E Takezaki N Masaki K Sugi K Honda H Adachi H Nishi Y Watanabe Y Nakamura M Shimada T Komatsu A Saito T Saoshiro H Harada T Sodeyama S Hayashi A Masumoto T Sando T Yamamoto H Sakai M Kobayashi T Muro M Koga Z Shums GL Norman H Ishibashi, Hepatology 2007 45 118 127 10.1002/hep.21472 17187436
190. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. DP Bogdanos C Liaskos A Pares G Norman EI Rigopoulou L Caballeria GN Dalekos J Rodes D Vergani, Hepatology 2007 45 1583 1584 10.1002/hep.21678 17538935
191. Prognosis in primary biliary cirrhosis: model for decision making. ER Dickson PM Grambsch TR Fleming LD Fisher A Langworthy, Hepatology 1989 10 1 7 10.1002/hep.1840100102 2737595